Echocardiographic and Exercise Test Findings in Patients With Dyslipidemia and Coronary Artery Disease Before and After Treatment With Simvastatin With or Without Fenofibrate

Reza  Karbasi-Afshar; Ayat  Shahmari; amin saburi

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Echocardiographic and Exercise Test Findings in Patients With Dyslipidemia and Coronary Artery Disease Before and After Treatment With Simvastatin With or Without Fenofibrate

Author(s):

Reza Karbasi-Afshar¹,

Ayat Shahmari²,

amin saburi^3,*

1Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

2Chemical injury research center, Baqiyatallah University of Medical Sciences. 2) Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

3Chemical Injury Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

International Cardiovascular Research Journal:Vol. 5, issue 4; e11217

Published online:Dec 30, 2011

Article type:Research Article

Received:Feb 27, 2017

Accepted:Jul 17, 2011

How to Cite:Reza Karbasi-AfsharAyat Shahmariamin saburiEchocardiographic and Exercise Test Findings in Patients With Dyslipidemia and Coronary Artery Disease Before and After Treatment With Simvastatin With or Without Fenofibrate.Int Cardiovasc Res J.5(4):e11217.

Abstract

Background: Various treatment protocols for dyslipidemia and coronary artery disease have been suggested. In spite of lipid-lowering effects, various effects of statins and fibrates have been reported in the literature.

Objectives: The aim of this study was to assess the cardiac efficacy of Simvastatin with or without fenofibrate on cardiac function.

Patients and Methods: A cohort study was conducted on 124 patients with dyslipidemia and coronary artery disease. Patients were randomly divided into two groups: the first group (n = 64) received Simvastatin (60 - 20 mg/day) and fenofibrate (200 mg/day), and the second group (n = 60) received Simvastatin (20 - 60 mg/day) alone. Treatment lasted 1 year, and the patients were evaluated after treatment.

Results: The mean age was 54.3 ± 6.5 years, and 53.2% of patients were male. Compared to baseline, after 12 months of treatment the lipid profiles of both groups decreased significantly (P < 0.05). The change in left-ventricular ejection fraction in the first group was statistically significant (P = 0.01). The exercise test time and metabolic equivalent of tasks index significantly increased in the first group (P = 0.014, P = 0.006 ), but these changes were not significant in the second group (P = 0.289, P = 0.744).

Conclusions: Lipid-regulating therapies including Simvastatin and fenofibrate improved myocardial function and reduced myocardial ischemia, so combined therapy is recommended for treating dyslipidemia in high-risk patients for cardiovascular problems.

Keywords

Coronary Artery Disease

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments